Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells by Carlet, Michela et al.
RESEARCH ARTICLE Open Access
Expression, regulation and function of
phosphofructo-kinase/fructose-biphosphatases
(PFKFBs) in glucocorticoid-induced apoptosis














Background: Glucocorticoids (GCs) cause apoptosis and cell cycle arrest in lymphoid cells and constitute a central
component in the therapy of lymphoid malignancies, most notably childhood acute lymphoblastic leukemia (ALL).
PFKFB2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-2), a kinase controlling glucose metabolism, was
identified by us previously as a GC response gene in expression profiling analyses performed in children with ALL
during initial systemic GC mono-therapy. Since deregulation of glucose metabolism has been implicated in
apoptosis induction, this gene and its relatives, PFKFB1, 3, and 4, were further analyzed.
Methods: Gene expression analyses of isolated lymphoblasts were performed on Affymetrix HGU133 Plus 2.0
microarrays. GCRMA normalized microarray data were analyzed using R-Bioconductor packages version 2.5.
Functional gene analyses of PFKFB2-15A and -15B isoforms were performed by conditional gene over-expression
experiments in the GC-sensitive T-ALL model CCRF-CEM.
Results: Expression analyses in additional ALL children, non-leukemic individuals and leukemic cell lines confirmed
frequent PFKFB2 induction by GC in most systems sensitive to GC-induced apoptosis, particularly T-ALL cells. The 3
other family members, in contrast, were either absent or only weakly expressed (PFKFB1 and 4) or not induced by
GC (PFKFB3). Conditional PFKFB2 over-expression in the CCRF-CEM T-ALL in vitro model revealed that its 2 splice
variants (PFKFB2-15A and PFKFB2-15B) had no detectable effect on cell survival. Moreover, neither PFKFB2 splice
variant significantly affected sensitivity to, or kinetics of, GC-induced apoptosis.
Conclusions: Our data suggest that, at least in the model system investigated, PFKFB2 is not an essential upstream
regulator of the anti-leukemic effects of GC.
Background
Glucocorticoid (GC)-induced apoptosis is a phenom-
enon of considerable physiologic and therapeutic signifi-
cance. Physiologically, it has been implicated in the
shaping of the immune repertoire and controlling
immune responses, and therapeutically it has been
exploited in the treatment of lymphoid malignancies,
most notably childhood acute lymphoblastic leukemia
(ALL), where good response to introductory hormone
treatment predicts a favourable over-all outcome [1].
GCs mediate most of their effects via their cognate
receptor (GR), a ligand-activated transcription factor of
the large nuclear transcription factor family. GC-induced
apoptosis critically depends on sufficient levels of GR
and subsequent alteration in gene expression, but the
precise nature of the GC-regulated genes responsible for
the anti-leukemic GC effects remains elusive (for
reviews see) [1-4].
To further address this issue, we previously exploited
a comparative expression profiling strategy using “whole
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delineate the GC response in primary lymphoblasts
from children suffering from ALL as well as from sev-
eral other biological systems of GC-sensitivity and resis-
tance [5]. Only a small number of genes were regulated
by GC in the majority of patients, which might reflect
the heterogeneity of the disease. Among these, PFKFB2
(6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-2),
a key regulator of glycolysis [6], was one of the most
frequently regulated genes. It was induced more than
4-fold in all 3 T-ALL cases as well as in the T-ALL cell
line CCRF-CEM. More than 2-fold induction was
observed in 8/10 children with precursor B-ALL and
1/1 adult with precursor B-ALL, but not in peripheral
blood lymphocytes from 2 healthy donors treated with
GC (such cells do not undergo apoptosis in response to
GC) [5]. Interestingly, the second GC-sensitive ALL cell
line tested in this study, 697/EU-3, and mouse thymo-
cytes failed to regulate PFKFB2.I nc o n c l u s i o n ,PFKFB2
was induced in many primary ALL cells (particularly
T-ALLs), but not in non-malignant lymphoid lineage
cells, raising the possibility that this gene might play a
functional role in GC-induced apoptosis in malignant
lymphoid cells such as ALL.
PFKFB2 is a member of a small gene family encoding
4 PFKFB isoenzymes. PFKFBs regulate formation and
degradation of fructose-2,6-biphosphate (F-2,6-P2), a
signalling molecule that controls glycolysis by regulating
phosphofructokinase-1 (PFK-1) activity [7,8]. PFKFBs
function as bifunctional enzymes: either they catalyze
the synthesis of F-2,6-P2, a potent allosteric effector of
PFK-1, via their 6-phosphofructo-2-kinase activity, or
they degrade F-2,6-P2 to fructose 6-phosphate by acting
as a fructose-2,6-biphosphatase. The kinase to
biphosphatase activity ratio (K:B) is determined by the
expression of specific isoforms, post-translational modi-
fications of the enzyme as well as by numerous catabolic
metabolites such as a-glycerol phosphate, citrate or
ATP/GTP levels in the cells [9]. Initially identified in rat
hepatocytes [8], 4 mammalian PFKFB isoenzymes have
been described in different tissues and developmental
stages, i.e., PFKFB1 in liver, skeletal muscles and fetal
tissues; PFKFB2 in heart, kidney, pancreas islets and
lymphoid tissues; PFKFB3 ubiquitously, particularly in
brain; and the testis-specific PFKFB4. All isoenzymes
share a highly conserved core structure comprising the
kinase and phosphatase activities. The isoenzymes and
their isoforms mainly differ in their N- and C-terminal
variable regions, however, all of them are active as
homodimers where the kinase domains come together
in a head-to-head fashion, whereas the phosphatase
domains function as monomers [7].
The human PFKFB2 gene codes for 2 isoforms (15A
and 15B) generated by alternative splicing of the
terminal exon 15, thus differing in their C-terminal
amino acid sequence [6]. Interestingly, in the more fre-
quently investigated PFKFB2-15A isoform, this 54
amino acid region contains two PKA-sensitive phos-
phorylation sites [10], i.e. Ser466 and Ser483, which
h a v eb e e ns h o w nt op l a ya ni m p o r t a n tr o l ei nt h er e g u -
lation of kinase- and phosphatase activity. Thus, phos-
phorylation of Ser466 increased kinase affinity to
fructose-6-phosphate (Fru-6-P), whereas dephosphoryla-
tion of the same residues entailed increased phosphatase
activity [11]. Since the PFKFB2-15B isoform lacks the
above kinase-activating phosphorylation sites, it might
lack kinase activity, raising the possibility that the 2 iso-
forms may have opposite functions.
Recently, alterations in glucose metabolism have been
implicated in cell death and survival decisions, particu-
larly in the lymphoid lineage [12] and in transformed
cells [13]. Thus, lymphocytes depend upon extracellular
signals transmitted via surface receptors and so-called
survival kinases, like PKB/Akt, to maintain their viabi-
lity. Part of these survival signals impinge on glucose
metabolism, e.g., by increasing the expression of glucose
transporters [14], with the net outcome of increased gly-
colysis and ATP production. Decline in glycolytic activ-
ity and ATP/ADP ratios results in integrity loss of
mitochondria, the central regulators of metabolism and
survival [15], with subsequent Bax-Bak dependent cyto-
chrome-C release and cell death. Similarly, tumor cells
depend upon glycolytic flux (Warburg effect) [16,17],
which provides them with building blocks required for
growth and energy. Hence, interference with “tumor
metabolism” has become a promising target for cancer
therapy [13].
The crucial role of PFKFBs in controlling glycolysis,
along with the fact that one member of this small gene
family, PFKFB2, was frequently regulated by GC in
malignant lymphoblasts from children suffering from
childhood ALL [5], makes this enzyme an interesting
candidate for the anti-leukemic effects of GC. To
further address this issue, we investigated expression
and GC regulation of all 4 known PFKFB family mem-
bers in the previously published and additional child-
hood ALL patients and in additional in vitro leukemic
systems. We found that only PFKFB2 showed consis-
tent GC-induction, particularly, although not exclu-
sively, in T-ALL systems. To assess a possible
functional significance of this regulation, we performed
conditional over-expression using the 2 known
PFKFB2 splice variants in the T-ALL cell model
CCRF-CEM in which both variants are dramatically
induced by GC. However, neither splice variant
replicated the apoptotic GC effects nor entailed
over-expression a consistent modulating effect on
GC-induced leukemia apoptosis.
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Patients, cell lines and tissue culture
The ALL children enrolled in this study were admitted
to the Department of Pediatrics, Innsbruck Medical Uni-
versity, or the St. Anna Kinderspital in Vienna from
September to December 2009, and treated according to
the BFM protocol 2000 (for protocol details see: http://
boriskononenko.files.wordpress.com/2009/09/1-proto-
koll-all-bfm-2000-mit-amendments-version-26-09-07-
d0bad0bed0bfd0b8d18f1.pdf). To analyze the GC
response in non-leukemic peripheral blood lymphocytes,
Ficoll-purified peripheral blood mononuclear cells from
2 healthy volunteers and 3 children with epilepsia trea-
ted with a single injection of GC were included. The
study was approved by the Ethics Committees of the
Innsbruck Medical University (EK1-1193-172/35 for
ALL children and UN2821 for epileptic children) and
the Kinderspital in Vienna, and written informed con-
sent was obtained from the patients and/or parents or
custodians. The characteristics of 3 children with T-ALL
and 10 with precursor B-ALL have been published pre-
viously [5], the remaining ALL children (3 T-ALLs and
15 precursor B-ALLs) showed similar clinical findings
[Rainer et al. in preparation]. All 3 patients with epilep-
sia (E3, a 14 year-old girl; E4, a 6 year-old boy; E5, an
11 year-old boy) had an idiopathic generalized epilepsia
without any evidence of metabolic, endocrinological,
immunological, hematological or infectious disease. The
6 year old girl (epilepsia diagnosed at 4 years of age)
was on Valproinate and Clobazam, the 9 year old girl
(epilepsia diagnosed at 8 year of age) on Valproinate
and Rufinamide, and E5 (epilepsia diagnosed at 2 years
of age) on Valproinate and Sultiam. Because of therapy-
refractory epilepsia, the 3 patients received their first
GC pulse therapy with dexamethasone (Fortecortin,
Merck, Vienna, Austria) 20 mg/m
2 administered intrave-
nously over 1 hour. Blood samples were taken at 2, 6
and 24 hours after drug administration.
The T-ALL cell lines CCRF-CEM-C7H2 [18], 6
GC-sensitive and 6 GC-resistant derivatives CCRF-
CEM-C7H2 [19], CEM-C7H2-2C8 [20], a CEM-C7H2
derivative with constitutive expression of the tetracy-
cline-regulated reverse transactivator, rtTA [21],
MOLT4 (CRL-1582, ATCC, Rockville, MD), and Jurkat
(untransfected and a rat GR-transfected derivative [22]),
the precursor B-cell lines 697/EU-3 (ACC 42, DSMZ,
Braunschweig, Germany), NALM6 (ACC 128, DSMZ),
RS4;11 (ACC 508, DSMZ) and AT-1 [23], and Burkitt’s
lymphoma Daudi (CCL-213, ATCC) were cultured in
RPMI 1640 supplemented with 10% fetal calf serum and
2 mM L-glutamine at 37°C, 5% carbon-dioxide and satu-
rated humidity. HEK293T packaging cells (ATCC, Man-
assas, VA) were cultured in DMEM supplemented as
above. The cells were free of mycoplasma infection and
their authenticity was verified by DNA fingerprinting, as
detailed previously [24]. Doxycycline was dissolved
(100 μg/ml) in phosphate-buffered saline and dexa-
methasone (10
-4M) in 100% ethanol. The final ethanol-
concentration in the dexamethasone-treated and control
cultures was maintained at 0.1%. All above reagents
were from Sigma (Vienna, Austria).
Expression profiling
Our procedure for generating mRNA expression profiles
on Affymetrix HGU133 plus 2.0 microarrays has been
detailed previously [5]. Briefly, RNA from peripheral
blood lymphoblasts of patients prior to, or at 6-8 or 24
hours after initiation of systemic GC monotherapy (fol-
lowing the BFM therapy protocol recommendations),
from healthy volunteers or epileptic children 6 hours
after GC treatment, and GC-sensitive or GC-resistant
cell lines, was converted into labeled target and hybri-
dized to Affymetrix HGU133 plus 2.0 microarrays
according to standard protocols. The microarray data
from the 31 ALL-patients and 5 non-leukemic indivi-
duals were normalized separately from those of the 12
cell lines using GCRMA [25] after positive evaluation of
comprehensive raw data quality assessment. The analysis
was performed in R using packages from Bioconductor
[26] version 2.5. Annotation of probe sets to genes
based on Affymetrix NetAffx annotation database ver-
sion 22 and location of probe sets relative to the 3’ end
of the transcripts were manually inspected using the
Ensembl genome browser for genes PFKFB1, PFKFB2,
PFKFB3 and PFKFB4. Microarray data for the samples
of the 13 ALL children and 2 healthy donors were pub-
lished previously [5] and are available at NCBI’sG E O
database (series GSE2677 and GSE2842). Microarray
data for the 12 cell lines (GSE22152) and 4 additional
non-leukemic individuals (GSE22779) have been depos-
ited at GEO.
Apoptosis determinations
Apoptosis was determined by FACS analysis of propi-
dium iodide (PI)-treated permeabilized cells [27] as pre-
viously detailed [28]. Briefly, cells were analyzed with a
FACScan cytometer (Becton Dickinson Biosciences, San
Jose, CA) in combination with CellQuest Pro software
(Becton Dickinson Biosciences) acquiring forward scat-
ter/sideward scatter, FL-2 H (log), and FL-3 H (linear).
In FL-2 H, the percentage of nuclei with reduced DNA-
content (SubG1 peak) was assessed.
Immunoblotting
Our immunoblotting procedure has been detailed recently
[29]. Briefly, proteins were extracted from 5 × 10
6 cells
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mixed with 40 μl loading buffer (4 × SSB, 5% b-mer-
captoethanol), denatured, fractionated on a 12.5% SDS-
PAGE and electroblotted onto nitrocellulose. The
membranes were incubated overnight with rabbit poly-
clonal antibodies against PFKFB2 (N-term, AP8146a,
Abgent), PFKFB2 phosphorylated Ser466 (University of
Dundee, UK) or mouse monoclonal antibodies against
a-TUBULIN (DM1A, CalBiochem, Nottingham, UK) as
a loading control. Specifically bound antibodies were
detected with anti-rabbit, anti-sheep or anti-mouse
horseradish-peroxidase-conjugated secondary antibodies
(Amersham Pharmacia Biotech, Uppsala, Sweden) and
visualized by chemiluminescence (ECL, Amersham)
and subsequent exposure to AGFA Curix X-ray films
for 1 second to 30 minutes.
Generation of CCRF-CEM derivatives with doxycycline-
induced PFKFB2-15A and -15B expression
The lentiviral conditional expression constructs pHR-
tetCMV-PFKFB2-15A and -15B (U264 and U265) were
generated using the GATEWAY™technology (Invitrogen,
Carlsbad, CA). The details of this procedure and the gen-
eration of stable clonal cell lines with tetracycline-regulated
expression of cDNAs cloned into such constructs has been
described previously [30]. In brief, human sequences coding
for PFKFB2-15A and -15B mRNA were PCR-amplified
using unique SacI-flanked forward primer 5’-GAGCTCT-
GTGCTCGACGAGCTCGT-3’ and XbaI-flanked isoform
specific reverse primers 5’-TCTAGATGGGTCTTCGGC-
TAGT-3’ (for PFKFB2-15A) and 5’-TCTAGAGTA-
GATCCCAGTCGT-3’ (for PFKFB2-15B) and cDNA from
CEM-C7H2 cells as template. The purified PCR product
was cloned into the SacI-XbaI site of pENTR-MCS-deltaN-
coI (U243), thereby generating pENTR207-PFKFB2-15A
(U260) and pENTR207-PFKFB2-15B (U263). Constructs
were sequence-verified and subsequently recombined into
the “destination vector” pHR-tetCMV-Dest-IRES-GFP
(U192) to generate pHR-tetCMV-PFKFB2-15A-ires-GFP
(U264) and pHR-tetCMV-PFKFB2-15B-ires-GFP (U265),
as previously described [30]. The lentiviral plasmids were
transfected into 293T packaging cells together with pVSV-
G and pSPAX (kindly provided by Didier Trono), and the
lentivirus-containing supernatants were used to transduce
CEM-C7H2-2C8, which constitutively express rtTA [20].
After limiting dilution cloning, three clonal cell lines
expressing the PFKFB2-15A isoform, termed CEM-
PFKFB2-15A#C3, #D6 and #E8, and three expressing
PFKFB2-15B named CEM-PFKFB2-15B#65, #66 and #95,
were selected for further experiments.
Real time RT-PCR
For high through-put real time RT-PCR, 50 μl of diluted
cDNA (2 ng/μl) were added to 50 μlo fT a q M a n
Universal MasterMix (Applied Biosystems, Foster City,
CA) and introduced into microfluidic cards containing
real time RT-PCR mixes for human PFKFB2
(Hs01015408_m1, Applied Biosystems) and TATA box-
binding protein for mRNA normalization (TBP,
Hs00427620_m1) according to the manufacturer’s guide-
lines. After equilibration at RT, the channels were filled
with 100 μl of reaction mix and centrifuged two times for
1 minute at 1000 rpm. Thereafter, the cards were sealed,
loaded into the HT7900 real time machine (Applied Bio-
systems), and run with a 2-step PCR thermo-protocol
that included an initial 94.5°C step for 10 min followed
by 40 cycles of 97°C for 15 sec alternating with 60°C for 1
min. Fluorescence signal intensities were read during the
60°C temperature step. Similarly, but on conventional
96 well plates, mRNA encoding the 2 PFKFB2 splice
variants 15A and 15B were quantified (Hs01015410_m1
and Hs01016554_m1, Applied Biosystems, for PFKFB2-
15A and PFKFB2-15B, respectively). Primary real-time
PCR data analysis was performed with SDS software
version 2.2.1, and further analysis was performed in
R (version 2.8). Data from 3 technically replicated mea-
surements were averaged and normalized to the internal
TBP control. Log2 fold change values (M values) were
calculated for 3 biological replicates by comparing nor-
malized real-time PCR data from GC-treated samples
against data from the corresponding control samples.
M values were averaged for the 3 biological replicates
and p-values were calculated (Student’s t-test) to test
against the null hypothesis of no differential expression
(mean M = 0).
Results
Expression and regulation of PFKFB1, 3 and 4 isoenzymes
in lymphocytes and malignant lymphoblasts
In a previous study, we showed that PFKFB2 is regu-
lated by GC in 11/13 children suffering from T-ALL
and preB-ALL [5]. To elucidate whether GC exclusively
regulated PFKFB2 in lymphoid cells, or whether other
PFKFB-isoenzymes are susceptible to GC-treatment as
well, we re-analyzed this data using the more robust
GCRMA normalization and included 18 additional ALL
patients undergoing GC therapy as well as 3 non-leuke-
mic children who received GC as part of their epilepsia
treatment, and 6 GC-sensitive and 6 GC-resistant deri-
vatives of the CEM-C7H2 T-ALL cell line. Additional
file 1, Table S3 summarizes mean expression levels
(mE-value) and mean GC regulation (mM-value) of the
3 isoforms, i.e. PFKFB1, PFKFB3 and PFKFB4,i nt h e s e
samples, organized in the following groups: T-ALLs,
precursor B-ALLs [as one group and as 3 separate
groups based on molecular defects: hyperdiploid, ETV6/
RUNX1 (previously TEL/AML1)t r a n s l o c a t i o n ,a n da
heterogeneous group termed “others"], non-leukemic
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derivates. Data for individual patients and cell lines are
depicted in Additional file 1, Tables S1 and S2. PFKFB1
and PFKFB4 isoenzymes were neither detectably
expressed in any of the investigated systems nor regu-
lated by GC. The brain/placenta- and tumor-specific
PFKFB3 isoenzyme showed expression levels comparable
to those of PFKFB2 (for comparisons see Table 1), how-
ever, in contrast to PFKFB2, its expression was not
upregulated by GC. Interestingly, expression of PFKFB3
was also observed in peripheral blood lymphocytes from
non-leukemic donors, indicating that this isoenzyme is
not restricted to placenta and brain or malignant tissues.
In conclusion, the PFKFB1 and 4 isoenzymes were
neither expressed nor regulated by GC and, hence,
might not play a role in the anti-leukemic GC effects.
PFKFB3 is expressed, but shows no significant GC-regu-
lation, excluding it from the list of likely candidate
genes.
Expression and regulation of PFKFB2-15A and -15B in
lymphocytes and malignant lymphoblasts
Next, we analyzed expression and GC regulation of the
2s p l i c ev a r i a n t so fPFKFB2 in the above biological sys-
tems. As summarized in Table 1, basal expression of
both PFKFB2 isoforms was variable: almost all T-ALLs
(known to show particularly strong response to GC) and
ETV6/RUNX1 positive ALLs (which have a good prog-
nosis) showed intermediate, all other subgroups, no or
very low expression. In all groups with detectable
expression of PFKFB2, mRNA levels (as measured by
signal intensity) of PFKFB2-15A were ~2-fold higher
than those of PFKFB2-15B. Concerning regulation,
T-ALL patients showed upregulation of both splice var-
iants at both time points, with mean M values between
1.7 and 2.7. This was also true for precursor B-ALL
patients, although the extent of regulation was consider-
ably less (mean M values between 0.6 and 1.1).
On an individual basis (Additional file 1, Table S1),
the T-ALL group appeared quite homogeneous, with
5/6 T-ALL children showing induction (as defined by an
M-value >1, i.e., >2-fold) after 6 and/or 24 hours of GC-
treatment. In hyperdiploid precursor B-ALL children,
isoform PFKFB2-15A was upregulated in 5/7 cases, with
one child presenting a tendency for downregulation (M-
value = -0.6), while PFKFB2-15B induction was present
only in 1 of the 7 children after 6 hours. The subgroup
of children with the ETV6/RUNX1 translocation showed
induction of PFKFB2-15A in 4/10 children, 2 showed a
slight downregulation, and 4 lacked PFKFB2-15A regula-
tion. A more homogeneous situation was observed for
the PFKFB2-15B isoform, where induction was detected
in 8/10 children, with the remaining 2 showing a ten-
dency to downregulate PFKFB2-15B after the first time
point. The last subgroup [low hyperdiploid, E2A/PBX1
translocation, t(8;4) and no chromosomal abnormalities]
showed upregulated PFKFB2-15A in 7/8 cases and
PFKFB2-15B in 4/8, and no regulation in the others. In
contrast to the ALL samples where PFKFB2 induction
was a frequent event, this was seen only once and only
for PFKFB2-15A in the non-leukemic donors. Concern-
ing the in vitro cell lines systems, all 6 GC-sensitive
CEM-C7H2 subclones showed clear induction of
PFKFB2-15A and -15B, with M values ranging from 1.6
to 4.0 (15A) and 1.1 to 2.3 (15B). The 6 R-lines resulted
in a remarkably heterogeneous picture, with M-values
ranging from 0.0 to 5.1 (15A) and 0.5 to 3.5 (15B).
Thus, despite the complexity of the expression profiling
data, PFKFB2 induction appeared to be a frequent fea-
ture in the GC response of T-lineage ALL and also
occurred in precursor B-ALL, albeit with lower fre-
quency. Moreover, PFKFB2 induction was absent or








samples 15A 15B 15A 6/8 h 15A 24 h 15B 6/8 h 15B 24 h
T-ALL (6) 6.3 ± 1.5 4.0 ± 1.9 1.7 ± 1.5 2.4 ± 1.4 1.9 ± 2.3 2.7 ± 2.3
Precursor B-ALL (25) 4.6 ± 2.7 3.0 ± 1.7 0.7 ± 0.8 1.1 ± 1.2 0.6 ± 0.9 0.9 ± 1.1
- hyperdiploid (7) 2.1 ± 0.7 1.5 ± 0.2 0.7 ± 0.6 0.9 ± 1.1 0.3 ± 0.4 0.3 ± 0.3
- EVT6/RUNX1 (10) 6.7 ± 1.7 4.4 ± 1.5 0.5 ± 1.1 0.8 ± 1.5 0.8 ± 1.1 1.1 ± 1.2
- others (8) 4.2 ± 2.7 2.4 ± 1.3 0.9 ± 0.8 1.5 ± 0.8 0.6 ± 0.8 1.3 ± 1.2
Non-leukemic donors (6*) 3.4 ± 0.2 2.0 ± 0.4 0.5 ± 0.7 ND 0.2 ± 0.3 ND
CEM-C7H2-S-lines (6) 2.3 ± 0.1 1.8 ± 0.1 3.1 ± 0.9 ND 1.8 ± 0.4 ND
CEM-C7H2-R-lines (6) 2.7 ± 0.3 1.8 ± 0.1 2.0 ± 2.0 ND 1.6 ± 1.3 ND
1Expression and regulation of PFKFB2 in ChALL patients, non-leukemic controls (adult healthy donors and epileptic children) and sensitive (S) and resistant (R)
CEM-C7H2 cell lines. Basal mean expression, before GC-treatment, is reported as mE-value ± SD; mean regulation was assessed after 6 and 24 hours and is
expressed as mM-value ± SD. The total number of cases is reported in brackets next to the subgroup name. Data were assessed by analysis of Affymetrix
HGU133 plus 2.0 microarrays. Abbreviation: ND, not determined.
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(non-leukemic donors, CEM-C7H2-R-lines).
Expression and regulation of PFKFB2 isoforms in
additional leukemic cell line models
To further address whether PFKFB2 regulation was
related to GC-sensitivity and/or preB-ALL and T-ALL
origin, we treated 9 leukemia cell lines with 10
-7M dexa-
methasone for 2, 6, 12 and 24 hours in biological tripli-
cates and performed real time RT-PCR using primers
covering the exon-3/exon-4 boundary present in both
splice variants (Figure 1A). To assess the contribution of
the individual splice variants, the 24 hour samples were
further analyzed using primers specific for PFKFB2-15A
and -15B (Figure 1B and 1C). As we previously reported
[31], the extent of GC sensitivity in these cell lines was
markedly different, i.e., untransfected Jurkat and
MOLT4 T-ALL cell lines as well as AT-1 precursor
B-ALL and Daudi Burkitt lymphoma cells were resistant
to GC-induced apoptosis, while all others were GC-sen-
sitive, although with varying kinetics (Additional file 1,
Figure S1). Effects of GC on cell cycle progression were
also determined [31] (Additional file 1, Figure S1) and
showed that GC-induced apoptosis was frequently pre-
ceded or accompanied by an increase of cells in the G1
phase of the cell division cycle, whereas the cell lines
resistant to GC-induced apoptosis were also resistant to
the GC effects on the cell cycle. The notable exception
was AT-1, in which G1 cell cycle arrest was observed in
the complete absence of apoptosis. As shown in Figure
1A, PFKFB2 induction was a frequent event in these cell
lines starting as soon as 2 hours after initial GC expo-
sure and increasing up to 24 hours. In those instances
where PFKFB2 induction was observed, both splice var-
iants appeared to be similarly regulated (Figure 1B).
There was no apparent correlation between PFKFB2
induction and GC sensitivity or T/B-lineage origin of
the leukemic cell lines. Concerning basal levels, the 2
splice variants showed co-expression across the panel of
leukemia cell lines (Figure 1C), with PFKFB2-15A levels
slightly exceeding those of -15B, thus resembling the
findings on the microarrays. In general, B-lineage cells
revealed lower expression levels than T-lineage cells
(again resembling the situation in patients), but there
was no apparent correlation between basal PFKFB2
levels and GC-sensitivity. For instance, GC-sensitive
C7H2 T-ALL cells had similar PFKFB2 levels as
GC-resistant MOLT4 T-ALL. The same was true for
GC-sensitive Jurkat
GR and their parental GC-resistant
Jurkat cell line.
Similar to the situation in patients, GC-dependent
induction was more pronounced in T-ALL cells than in
B-lineage leukemias, but there was no obvious correla-
tion with GC sensitivity across all samples. In the Jurkat
T-ALL system, however, induction of PFKFB2 correlated
with GC sensitivity, as we have similarly seen in the
CCRF-CEM system using microarray technology.
Although we were unable to definitively prove regula-
tion at the protein level (for reasons explained in Addi-
tional file 1), the combined clinical and experimental
mRNA data were compatible with the notion that
induction of PFKFB2 contributes to GC-induced apop-
tosis, particularly in T-ALL cells.
Effect of conditional over-expression of PFKFB2 isoforms
on cell viability and GC-sensitivity
To evaluate a possible contribution of increased PFKFB2
levels to the anti-leukemic effects of GC, we generated
cell lines conditionally overexpressing either PFKFB2-
15A or -15B in a doxycycline-dependent manner. Three
clones for each isoform (termed CEM-PFKFB2-15A#C3,
#D6, #E8 and CEM-PFKFB2-15B#65, #66, #95, respec-
tively) were analyzed for regulation of the transgene by
quantitative RT-PCR and immunoblotting (Figure 2 and
Additional file 1, Figure S2 and S3). In all instances we
obtained doxycycline dose- and time-dependent induc-
tion of the PFKFB2 splice variants to levels as high as,
or even exceeding, those obtained after GC treatment.
Nevertheless, no effect was observed on cell viability,
suggesting that induction of either PFKFB2 splice var-
iant is not sufficient to explain apoptosis seen after GC
exposure (Figure 3). In addition, the FACS data of
PI-stained nuclei strongly suggested that there was no
effect on cell cycle progression or GC-induced cell cycle
arrest (data not shown). To investigate whether trans-
genic expression of PFKFB2 resulted in altered GC sus-
ceptibility, we treated the above T-ALL cell lines with
10
-7Md e x a m e t h a s o n ei nt h ep r e s e n c ea n da b s e n c eo f
doxycycline (i.e., with and without transgenic PFKFB2
induction) and analyzed the extent of apoptosis (as
measured by FACS analysis of propidium iodide incor-
poration) at various time points (Figure 3). Neither
PFKFB2-15A nor -15B over-expression significantly
changed GC sensitivity in these cells, although both iso-
forms were clearly detectable by immunoblotting (Figure
3C). Moreover, in the case of PFKFB2-15A where corre-
sponding analyses can be performed, we observed that
the activation-specific Ser466 [11] was phosphorylated,
suggesting that the transgenic protein was not only
sufficiently well expressed, but also active as a kinase. In
conclusion, the data show that, at least in the investi-
gated model system, neither PFKFB2-15A nor -15B
over-expression mimics the anti-leukemic effects of GC,
nor does it alter GC sensitivity.
Discussion
In this study, we addressed the possible functional sig-
nificance of GC-dependent PFKFB2 regulation in
Carlet et al. BMC Cancer 2010, 10:638
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Page 6 of 11Figure 1 Expression/regulation of PFKFB2 and its splice variants in leukemic cell lines. (A) The cell lines were cultured as indicated in the
presence of 10
-7M dexamethasone or 0.1% ethanol as vehicle control, and analyzed for mRNA expression of PFKFB2 (using a primer pair
recognizing both splice variants) and TBP as control by quantitative RT-PCR on microfluidic cards. TBP-normalized PFKFB2 expression levels (ΔCT)
were used to determine GC regulation (ΔΔCT) expressed as mean M-values ± standard deviation. Asterisks indicate p-values of <0.05. PFKFB2 was
undetectable in NALM6 (at 2, 6 and 12 hours) and AT-1 cells prior to, but clearly detectable, after GC treatment. Thus, the extent of regulation
(ΔΔCT) could not be quantified. Asterisks indicate statistically significant changes of expression (p < 0.05) as calculated by a paired t-test from 3
replicated values. Regulations were considered biologically significant if the extent of differential expression was larger than 2-fold (indicated by
the dashed horizontal line M = 1). (B) Regulation of PFKFB2 variants (open circles for PFKFB2-15A, black circles for PFKFB2-15B) after 24 hour
exposure to 10
-7M dexamethasone is expressed as mean M-value (ΔΔCT) ±SD. Asterisks indicate p < 0.05. In NALM6 cells, PFKFB2-15B was
induced by GC as well. However, since the expression level in the ethanol-treated control sample was below the limit of detection, it was not
possible to derive an M-value. In the 697/EU-3 cells, PFKFB-15B was undetectable after 24 hour GC exposure, which might be explained by the
fact that PFKFB2 levels in 697/EU-3 were at the limit of detection of this assay or suggest a weak down-regulation. (C) Basal expression of the
PFKFB2-15A (white bars) and -15B (grey bars) splice variants was detected in the same cell lines using specific Taqman quantitative RT-PCR and
normalized to TBP. Expression levels are reported as minus mean ΔCT (ΔCT, CT values obtained with TBP primers minus CT values obtained with
PFKFB2-15A or -15B primers, respectively). In AT-1, both splice variants, and in NALM6 the PFKFB2-15A variant, could be detected in the absence
of dexamethasone, although at very low levels (presumably due to slightly higher efficiency of these RT-PCRs compared to the RT-PCR for both
variants).
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Page 7 of 11primary malignant lymphoblasts and leukemic cell line
models. PFKFB2 was identified by microarray analysis of
lymphoblasts isolated from GC-treated children suffer-
i n gf r o mA L L[ 5 ]a so n eo ft h em o s tp r o m i s i n gc a n d i -
date genes, since it was regulated in the majority of
patients and its deregulation should entail disturbances
in glucose metabolism which, in turn, have been impli-
cated in cell death induction in general [12,13]. More
specifically, GC resistance was associated with increased
glucose consumption [32], and interference with this
g l u c o s ed e p e n d e n c yb ys i m u l t a n e o u sa d d i t i o no f
2-deoxy-D-glucose (2-DG) increased in vitro sensitivity
to GC [32,33]. We therefore hypothesized that the apop-
totic effect of GC might be triggered, at least in part, by
reducing the glycolytic activity of the cell, and that this
GC effect is mediated by upregulation of PFKFB2.
To further test this hypothesis, we first performed
detailed expression and regulation analysis of the 2
splice variants of this gene and of the 3 other members
of the PFKFB gene family in several GC-sensitive and
-resistant leukemic T-ALL and preB-ALL cell lines and
peripheral blood cells from non-leukemic individuals.
This made a possible contribution of the 3 other PFKFB
isoenzymes to GC effects in such cells highly unlikely:
PFKFB1 and -4 were not, or only very moderately,
expressed and were not regulated by GC treatment,
PFKFB3 was expressed, but not significantly regulated
by GC (Additional file 1, Table S3). Concerning
PFKFB2,w eo b s e r v e dt h a tb o t hs p l i c ev a r i a n t sw e r e
expressed at similar levels (with PFKFB2-15A somewhat
higher than -15B) and were co-regulated in most sys-
tems. Although the number of patients is limited, GC
induction was more pronounced (both in terms of fre-
quency and extent of regulation) in T-ALLs compared
to precursor B-ALLs. Concerning correlation with GC
sensitivity, all ALL children were considered GC-sensi-
tive because all showed a reduction in blast counts
within the first 24 to 48 hours of treatment. Three
Figure 2 Characterization of T-ALL cell lines with conditional PFKFB2-15A and -15B expression. CEM-PFKFB2-15A #D6 (Figure 2A) and
CEM-PFKFB2-15B #66 (Figure 2B) cells expressing PFKFB2-15A and -15B in a doxycycline-dependent manner, respectively, were cultured in the
presence of increasing concentration of doxycycline (Dox) for the indicated time and analysed for PFKFB2 expression (see Figures S2 and S3 for
the corresponding data for the remaining 4 cell lines used in this study). mRNA expression was assessed by using quantitative real time RT-PCR
targeting the exons-3/exon-4 boundary present in both splice variants. The data derive from 3 biological replicates analyzed in triplicate and
expressed as -ΔCT (i.e., CT value of PFKFB2-15A minus CT value of TBP). PFKFB2 protein was detected by immunoblotting with antibodies against
PFKFB2 and a-TUBULIN as loading control (right panels). Shown are representative examples of cells treated with the indicated amounts of
doxycycline for 24 hours.
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Page 8 of 11children (24, 699, 724) were classified as prednisolone
poor responders based on a blast count of >1000/μlo n
day 8, yet they also showed GC-induction of at least 1
of the variants at 1 or both time points. GC-resistant
cell lines and non-leukemic individuals (whose periph-
eral blood lymphocytes are considered resistant to
GC-induced apoptosis) [34,35], clearly showed less GC-
induction of PFKFB2. Thus, even though the correlation
of GC-induction of PFKFB2 and cell death was not
complete, the extended expression/regulation analyses
further supported a possible role of PFKFB2 in
GC-induced apoptosis, particularly in T-ALL cells.
We therefore performed conditional over-expression
of both PFKFB2 splice variants in a GC-sensitive T-ALL
model system, but these experiments showed no detect-
able effect of PFKFB2-15A or -15B on cell death, nor
did their over-expression change sensitivity to, or
kinetics of, GC-induced apoptosis. While these data
clearly showed that induction of neither of the 2 splice
variants suffices to elicit the anti-leukemic GC effects,
Figure 3 Conditional PFKFB2 over-expression in CCRF-CEM T-ALL cells has no effect on GC-induced apoptosis. CEM-PFKFB2-15A#C3, #D6
and #E8 cells (expressing PFKFB2-15A in a doxycycline-dependent manner, Figure 3A) and CEM-PFKFB2-15A#65, #66 and #95 cells (expressing
PFKFB2-15B in a doxycycline-dependent manner, Figure 3B) were cultured in the absence of doxycycline and dexamethasone (open square), in
the presence of 10
-7 M dexamethasone (open circle) or 500 ng/ml doxycycline (closed square), and with the combination of both (closed circle)
for the indicated time and subjected to apoptosis determination using flow cytometric analyses of propidium iodide-stained nuclei ("apoptosis”
refers to percent of events in the SubG1 window). Since all 3 cell lines for each isoform gave similar results, the data were pooled. Shown are
the mean values±SD of specific apoptosis derived from biological triplicates of the 3 cell lines (i.e., 9 measurements per time point and
treatment). Figure 3C: PFKFB2-15A and -15B protein expression was analyzed in the indicated cell lines with and without 24 h doxyxcyline
induction (Dox, 500 ng/ml) and in the absence and presence of dexamethasone (Dex, 10
-7M) by immunoblotting using an antibody against the
shared N-terminal region (top panel) or Ser466 phosphorylated PFKFB2-15A (3
rd panel) with a-TUBULIN serving as loading control.
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Page 9 of 11further work is needed to dissect whether the effects of
GC on glucose metabolism are mediated by induction of
PFKFB2 (as we hypothesized based on the reported role
of PFKFB enzymes) or whether other, perhaps less
obvious, pathways are involved. Preliminary experiments
addressing this issue suggested that, surprisingly, over-
expression of both PFKFB2 splice variants seems to
have little, if any, effect on lactate and ATP production,
two indicators of glycolytic activity that are reduced
after GC treatment. Thus, the current data show that
induction of the 2 splice variants of PFKFB2 cannot
explain the anti-leukemic GC effects. Whether altera-
tions of glucose metabolism by other GC-dependent
mechanisms might contribute to GC-induced leukemia
apoptosis requires further investigations.
Conclusions
Our study demonstrated that the heart-specific PFKFB2
isoenzyme is expressed and specifically induced by GC
in malignant lymphoid cells, however, functional analysis
of this gene in the human T-ALL cell line model CCRF-
CEM revealed that its over-expression does not explain
the anti-leukemic effects of GC.
Additional material
Additional file 1: Supplement. Supplementary information consisting of
3 Tables, 4 Figures and additional discussion section.
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